Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Gespeichert in:

Autor*in:	Dominika Wcisło-Dziadecka [verfasserIn] Beniamin Grabarek [verfasserIn] Andrzej Swinarew [verfasserIn] Beata Rozwadowska [verfasserIn] Nikola Zmarzły [verfasserIn] Joanna Gola [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine

Übergeordnetes Werk:	In: Advances in Dermatology and Allergology - Termedia Publishing House, 2016, 37(2020), 2, Seite 262-268
Übergeordnetes Werk:	volume:37 ; year:2020 ; number:2 ; pages:262-268

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.5114/ada.2020.94847

Katalog-ID:	DOAJ067001424

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ067001424
003	DE-627
005	20230501185141.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.5114/ada.2020.94847 \|2 doi
035			\|a (DE-627)DOAJ067001424
035			\|a (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RL1-803
050		0	\|a RC31-1245
100	0		\|a Dominika Wcisło-Dziadecka \|e verfasserin \|4 aut
245	1	0	\|a Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
650		4	\|a anti-tnf therapy
650		4	\|a psoriasis
650		4	\|a molecular marker
650		4	\|a resistance in therapy
650		4	\|a personalized medicine
653		0	\|a Dermatology
653		0	\|a Internal medicine
700	0		\|a Beniamin Grabarek \|e verfasserin \|4 aut
700	0		\|a Andrzej Swinarew \|e verfasserin \|4 aut
700	0		\|a Beata Rozwadowska \|e verfasserin \|4 aut
700	0		\|a Nikola Zmarzły \|e verfasserin \|4 aut
700	0		\|a Joanna Gola \|e verfasserin \|4 aut
773	0	8	\|i In \|t Advances in Dermatology and Allergology \|d Termedia Publishing House, 2016 \|g 37(2020), 2, Seite 262-268 \|w (DE-627)647656531 \|w (DE-600)2596142-1 \|x 22990046 \|7 nnns
773	1	8	\|g volume:37 \|g year:2020 \|g number:2 \|g pages:262-268
856	4	0	\|u https://doi.org/10.5114/ada.2020.94847 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 \|z kostenfrei
856	4	0	\|u https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1642-395X \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2299-0046 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 37 \|j 2020 \|e 2 \|h 262-268

Indexfelder

author_variant	d w d dwd b g bg a s as b r br n z nz j g jg
matchkey_str	article:22990046:2020----::opeesvmlclrnciiaaayioaaiuaadtnrethrpuiptnil
hierarchy_sort_str	2020
callnumber-subject-code	RL
publishDate	2020
allfields	10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268
spelling	10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268
allfields_unstemmed	10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268
allfieldsGer	10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268
allfieldsSound	10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268
language	English
source	In Advances in Dermatology and Allergology 37(2020), 2, Seite 262-268 volume:37 year:2020 number:2 pages:262-268
sourceStr	In Advances in Dermatology and Allergology 37(2020), 2, Seite 262-268 volume:37 year:2020 number:2 pages:262-268
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine
isfreeaccess_bool	true
container_title	Advances in Dermatology and Allergology
authorswithroles_txt_mv	Dominika Wcisło-Dziadecka @@aut@@ Beniamin Grabarek @@aut@@ Andrzej Swinarew @@aut@@ Beata Rozwadowska @@aut@@ Nikola Zmarzły @@aut@@ Joanna Gola @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	647656531
id	DOAJ067001424
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ067001424</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501185141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5114/ada.2020.94847</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ067001424</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Dominika Wcisło-Dziadecka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-tnf therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">psoriasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular marker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">resistance in therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beniamin Grabarek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrzej Swinarew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Rozwadowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikola Zmarzły</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Gola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Dermatology and Allergology</subfield><subfield code="d">Termedia Publishing House, 2016</subfield><subfield code="g">37(2020), 2, Seite 262-268</subfield><subfield code="w">(DE-627)647656531</subfield><subfield code="w">(DE-600)2596142-1</subfield><subfield code="x">22990046</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:262-268</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5114/ada.2020.94847</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1642-395X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2299-0046</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">262-268</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Dominika Wcisło-Dziadecka
spellingShingle	Dominika Wcisło-Dziadecka misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
authorStr	Dominika Wcisło-Dziadecka
ppnlink_with_tag_str_mv	@@773@@(DE-627)647656531
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RL1-803
illustrated	Not Illustrated
issn	22990046
topic_title	RL1-803 RC31-1245 Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine
topic	misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine
topic_unstemmed	misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine
topic_browse	misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Advances in Dermatology and Allergology
hierarchy_parent_id	647656531
hierarchy_top_title	Advances in Dermatology and Allergology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)647656531 (DE-600)2596142-1
title	Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
ctrlnum	(DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920
title_full	Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
author_sort	Dominika Wcisło-Dziadecka
journal	Advances in Dermatology and Allergology
journalStr	Advances in Dermatology and Allergology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	262
author_browse	Dominika Wcisło-Dziadecka Beniamin Grabarek Andrzej Swinarew Beata Rozwadowska Nikola Zmarzły Joanna Gola
container_volume	37
class	RL1-803 RC31-1245
format_se	Elektronische Aufsätze
author-letter	Dominika Wcisło-Dziadecka
doi_str_mv	10.5114/ada.2020.94847
author2-role	verfasserin
title_sort	comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
callnumber	RL1-803
title_auth	Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
url	https://doi.org/10.5114/ada.2020.94847 https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html https://doaj.org/toc/1642-395X https://doaj.org/toc/2299-0046
remote_bool	true
author2	Beniamin Grabarek Andrzej Swinarew Beata Rozwadowska Nikola Zmarzły Joanna Gola
author2Str	Beniamin Grabarek Andrzej Swinarew Beata Rozwadowska Nikola Zmarzły Joanna Gola
ppnlink	647656531
callnumber-subject	RL - Dermatology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.5114/ada.2020.94847
callnumber-a	RL1-803
up_date	2024-07-03T23:04:53.910Z
_version_	1803600940405620736
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ067001424</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501185141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5114/ada.2020.94847</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ067001424</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Dominika Wcisło-Dziadecka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-tnf therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">psoriasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular marker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">resistance in therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beniamin Grabarek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrzej Swinarew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Rozwadowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikola Zmarzły</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Gola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Dermatology and Allergology</subfield><subfield code="d">Termedia Publishing House, 2016</subfield><subfield code="g">37(2020), 2, Seite 262-268</subfield><subfield code="w">(DE-627)647656531</subfield><subfield code="w">(DE-600)2596142-1</subfield><subfield code="x">22990046</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:262-268</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5114/ada.2020.94847</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1642-395X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2299-0046</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">262-268</subfield></datafield></record></collection>
score	7.401269

Nicht das Richtige dabei?

Schreiben Sie uns!

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?